Subcutaneous Trastuzumab: An Observational Study of Safety and Tolerability in Patients With Early HER2-Positive Breast Cancer
Conclusion: The research suggests that subcutaneous trastuzumab is comparable in effectiveness and safety to the intravenous administration. Regional-specific studies may provide valuable insights into demographic factors influencing treatment outcomes in Peru or other countries. Furthermore, it cou...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-01-01
|
| Series: | International Journal of Breast Cancer |
| Online Access: | http://dx.doi.org/10.1155/2024/9551710 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849400047251226624 |
|---|---|
| author | Iris Otoya Natalia Valdiviezo Zaida Morante Cindy Calle Yomali Ferreyra Norma Huarcaya-Chombo Gabriela Polo-Mendoza Carlos Castañeda Tatiana Vidaurre Silvia P. Neciosup Mónica J. Calderón Henry L. Gomez |
| author_facet | Iris Otoya Natalia Valdiviezo Zaida Morante Cindy Calle Yomali Ferreyra Norma Huarcaya-Chombo Gabriela Polo-Mendoza Carlos Castañeda Tatiana Vidaurre Silvia P. Neciosup Mónica J. Calderón Henry L. Gomez |
| author_sort | Iris Otoya |
| collection | DOAJ |
| description | Conclusion: The research suggests that subcutaneous trastuzumab is comparable in effectiveness and safety to the intravenous administration. Regional-specific studies may provide valuable insights into demographic factors influencing treatment outcomes in Peru or other countries. Furthermore, it could represent a more accessible alternative, potentially enhancing patient adherence and optimizing healthcare resource logistics. |
| format | Article |
| id | doaj-art-a5127c98c19d481e82e3aaf6183aa54d |
| institution | Kabale University |
| issn | 2090-3189 |
| language | English |
| publishDate | 2024-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | International Journal of Breast Cancer |
| spelling | doaj-art-a5127c98c19d481e82e3aaf6183aa54d2025-08-20T03:38:11ZengWileyInternational Journal of Breast Cancer2090-31892024-01-01202410.1155/2024/9551710Subcutaneous Trastuzumab: An Observational Study of Safety and Tolerability in Patients With Early HER2-Positive Breast CancerIris Otoya0Natalia Valdiviezo1Zaida Morante2Cindy Calle3Yomali Ferreyra4Norma Huarcaya-Chombo5Gabriela Polo-Mendoza6Carlos Castañeda7Tatiana Vidaurre8Silvia P. Neciosup9Mónica J. Calderón10Henry L. Gomez11Department of Medical OncologyDepartment of Medical OncologyDepartment of Medical OncologyDepartment of Medical OncologyDepartment of BioengineeringFaculty of Science and EngineeringDepartment of BioengineeringDepartment of Medical OncologyDepartment of Medical OncologyDepartment of Medical OncologyDepartment of Medical OncologyDepartment of Medical OncologyConclusion: The research suggests that subcutaneous trastuzumab is comparable in effectiveness and safety to the intravenous administration. Regional-specific studies may provide valuable insights into demographic factors influencing treatment outcomes in Peru or other countries. Furthermore, it could represent a more accessible alternative, potentially enhancing patient adherence and optimizing healthcare resource logistics.http://dx.doi.org/10.1155/2024/9551710 |
| spellingShingle | Iris Otoya Natalia Valdiviezo Zaida Morante Cindy Calle Yomali Ferreyra Norma Huarcaya-Chombo Gabriela Polo-Mendoza Carlos Castañeda Tatiana Vidaurre Silvia P. Neciosup Mónica J. Calderón Henry L. Gomez Subcutaneous Trastuzumab: An Observational Study of Safety and Tolerability in Patients With Early HER2-Positive Breast Cancer International Journal of Breast Cancer |
| title | Subcutaneous Trastuzumab: An Observational Study of Safety and Tolerability in Patients With Early HER2-Positive Breast Cancer |
| title_full | Subcutaneous Trastuzumab: An Observational Study of Safety and Tolerability in Patients With Early HER2-Positive Breast Cancer |
| title_fullStr | Subcutaneous Trastuzumab: An Observational Study of Safety and Tolerability in Patients With Early HER2-Positive Breast Cancer |
| title_full_unstemmed | Subcutaneous Trastuzumab: An Observational Study of Safety and Tolerability in Patients With Early HER2-Positive Breast Cancer |
| title_short | Subcutaneous Trastuzumab: An Observational Study of Safety and Tolerability in Patients With Early HER2-Positive Breast Cancer |
| title_sort | subcutaneous trastuzumab an observational study of safety and tolerability in patients with early her2 positive breast cancer |
| url | http://dx.doi.org/10.1155/2024/9551710 |
| work_keys_str_mv | AT irisotoya subcutaneoustrastuzumabanobservationalstudyofsafetyandtolerabilityinpatientswithearlyher2positivebreastcancer AT nataliavaldiviezo subcutaneoustrastuzumabanobservationalstudyofsafetyandtolerabilityinpatientswithearlyher2positivebreastcancer AT zaidamorante subcutaneoustrastuzumabanobservationalstudyofsafetyandtolerabilityinpatientswithearlyher2positivebreastcancer AT cindycalle subcutaneoustrastuzumabanobservationalstudyofsafetyandtolerabilityinpatientswithearlyher2positivebreastcancer AT yomaliferreyra subcutaneoustrastuzumabanobservationalstudyofsafetyandtolerabilityinpatientswithearlyher2positivebreastcancer AT normahuarcayachombo subcutaneoustrastuzumabanobservationalstudyofsafetyandtolerabilityinpatientswithearlyher2positivebreastcancer AT gabrielapolomendoza subcutaneoustrastuzumabanobservationalstudyofsafetyandtolerabilityinpatientswithearlyher2positivebreastcancer AT carloscastaneda subcutaneoustrastuzumabanobservationalstudyofsafetyandtolerabilityinpatientswithearlyher2positivebreastcancer AT tatianavidaurre subcutaneoustrastuzumabanobservationalstudyofsafetyandtolerabilityinpatientswithearlyher2positivebreastcancer AT silviapneciosup subcutaneoustrastuzumabanobservationalstudyofsafetyandtolerabilityinpatientswithearlyher2positivebreastcancer AT monicajcalderon subcutaneoustrastuzumabanobservationalstudyofsafetyandtolerabilityinpatientswithearlyher2positivebreastcancer AT henrylgomez subcutaneoustrastuzumabanobservationalstudyofsafetyandtolerabilityinpatientswithearlyher2positivebreastcancer |